Indegene Limited has announced the approval of Restricted Stock Unit (RSU) grants under its RSU 2020 Plan. The company's Nomination and Remuneration Committee approved the grants on December 31, 2025, as part of its employee compensation strategy.

RSU Grant Details

The committee has approved grants of 5,08,368 RSUs to eligible employees of the company. These grants are structured in compliance with SEBI (Share Based Employee Benefits) Regulations, 2021.

Vesting Schedule and Exercise Terms

The RSU grants follow a structured four-year vesting schedule designed to retain talent and align employee interests with company performance:

• Year 1: 25% of granted options vest after completion of one year from grant date
• Year 2: 25% of granted options vest after completion of two years from grant date
• Year 3: 25% of granted options vest after completion of three years from grant date
• Year 4: 25% of granted options vest after completion of four years from grant date

Employees will have a maximum exercise period of 75 days from the respective vesting date of each tranche to exercise their options.

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement also complies with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The company has made the relevant information available on its official website at https://www.indegene.com/ for stakeholder reference. Company Secretary and Compliance Officer Srishti Ramesh Kaushik signed the regulatory filing on behalf of Indegene Limited.

Indegene Limited has completed an internal restructuring transaction involving the acquisition of 100% equity shares in Trilogy Writing & Consulting Inc., a Canada-based medical writing company. The acquisition was finalized on December 31, 2025, through a Share Purchase Agreement signed by the company's wholly owned subsidiaries.

Transaction Structure

The acquisition was executed by Indegene, Inc. (USA) and Trilogy Writing and Consulting GmbH, both wholly owned subsidiaries of Indegene Limited. The transaction involved acquiring 100% equity shares in Trilogy Writing & Consulting Inc., formerly known as Trilogy Writing and Consulting ULC (Canada).

Target Company Profile

Trilogy Writing & Consulting Inc. is a Canada-based company specializing in medical writing services. The company operates within the healthcare industry and has demonstrated consistent growth in recent years.

The target company's turnover has shown significant growth, increasing from CAD 369,636 in 2022 to CAD 892,361 in 2024, representing substantial year-over-year expansion in its medical writing business.

Regulatory Compliance

The transaction has been disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that:

• The transaction falls within related party transactions
• No promoter, promoter group, or group companies have any interest in the entity being acquired
• The transaction was conducted on an arm's length basis
• No governmental or regulatory approvals were required for the acquisition

Post-Acquisition Structure

Following the completion of this internal restructuring, Trilogy Writing & Consulting Inc. will cease to be a subsidiary of Trilogy Writing and Consulting GmbH and will become a wholly owned subsidiary of Indegene, Inc. This restructuring aligns with the company's strategic organizational objectives while maintaining full control over the medical writing capabilities of the acquired entity.

The acquisition strengthens Indegene's presence in the medical writing sector and enhances its service offerings within the healthcare industry. The transaction represents a strategic internal reorganization designed to optimize the company's subsidiary structure and operational efficiency.